Vonoprazan/amoxicillin
 | |
| Combination of | |
|---|---|
| Vonoprazan | Potassium-competitive acid blocker |
| Amoxicillin | Beta-lactam antibiotic |
| Clinical data | |
| Trade names | Voquezna Dual Pak |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
Vonoprazan/amoxicillin, sold under the brand name Voquezna Dual Pak among others, is a co-packaged medication used for the treatment of Helicobacter pylori (H. pylori) infection.[1] It contains vonoprazan (as the fumarate), a potassium-competitive acid blocker and amoxicillin, a beta-lactam antibiotic.[1] It is taken by mouth.[1]
The co-packaged medication was approved for medical use in the United States in May 2022.[1][2][3][4]
Medical uses
[edit]Vonoprazan/amoxicillin is indicated for the treatment of H. pylori infection in adults.[1][5]
Research
[edit]The dual therapy of using vonoprazan with amoxicillin has been investigated for the treatment of H. pylori infection[6] and also compared with the triple therapy of using vonoprazan, amoxicillin, and clarithromycin for the eradication of H. pylori infection.[7] Both treatments have been found to be effective.[6][7] As of 2024,[update] evidence indicates that vonoprazan/amoxicillin therapy has similar efficacy to bismuth-containing quadruple therapies in eliminating H. pylori.[8]
References
[edit]- ^ a b c d e f "Voquezna Dual Pak- vonoprazan fumarate and amoxicillin kit Voquezna Triple Pak- vonoprazan fumarate, amoxicillin and clarithromycin kit". DailyMed. 21 June 2022. Archived from the original on 3 July 2022. Retrieved 3 July 2022.
- ^ a b "Phathom Pharmaceuticals Announces FDA Approval of Voquezna Triple Pak (vonoprazan, amoxicillin, clarithromycin) and Voquezna Dual Pak (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults" (Press release). Phathom Pharmaceuticals. 3 May 2022. Archived from the original on 10 May 2022. Retrieved 9 May 2022 – via GlobeNewswire.
- ^ "Voquezna Dual Pak (amoxicillin and vonoprazan) FDA Approval History". Drugs.com. Archived from the original on 16 May 2022. Retrieved 16 May 2022.
- ^ "FDA NDA approval" (PDF). U.S. Food and Drug Administration (FDA). Archived (PDF) from the original on 12 May 2022. Retrieved 12 May 2022.
- ^ "Voquezna Dual Pak (vonoprazan/amoxicillin) monograph". Medscape. 5 May 2022. Archived from the original on 11 May 2022. Retrieved 11 May 2022.
- ^ a b Suzuki S, Gotoda T, Kusano C, Ikehara H, Ichijima R, Ohyauchi M, et al. (June 2020). "Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan". Gut. 69 (6): 1019–1026. doi:10.1136/gutjnl-2019-319954. PMC 7282559. PMID 31915235.
- ^ a b Furuta T, Yamade M, Kagami T, Uotani T, Suzuki T, Higuchi T, et al. (November 2020). "Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori". Digestion. 101 (6): 743–751. doi:10.1159/000502287. PMID 31434101. S2CID 201277349.
- ^ Pai L, Patil S, Liu S, Wen F (2023). "A growing battlefield in the war against biofilm-induced antimicrobial resistance: insights from reviews on antibiotic resistance". Front Cell Infect Microbiol. 13: 1327069. doi:10.3389/fcimb.2023.1327069. PMC 10770264. PMID 38188636.
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |